Multimodal treatment of hepatocellular carcinoma.
Our multimodal treatment of hepatocellular carcinoma (HCC) has brought about a significant improvement of the survival rate. It consists of a combination of hepatectomy and transcatheter arterial embolization using lipiodol (L-TAE). In order to facilitate L-TAE, we have developed a special catheter with notches. A group of patients with HCC (124 cases), excluding cases with absolutely non-curative resections and operative deaths, were treated between December 1980 and November 1986. Each case was treated for more than 1 year after hepatectomy. The patients were divided into two groups: A, patients with a single tumor not larger than 5 cm, and B, cases with larger tumors or more than one lesion. Some patients in each group were treated with L-TAE after hepatectomy. In group A, there was no significant difference in survival between treated and non-treated cases. In group B, L-TAE gave a significantly better survival than no postoperative treatment.
Shimamura
Y
Y
Department of Surgery, National Matsudo Hospital, Chiba, Japan.
Takenaka
Y
Y
Ishii
M
M
Shima
Y
Y
Taniguchi
H
H
Kitai
Y
Y
Watanabe
H
H
Sugai
S
S
Takashi
A
A
Kitaya
T
T
D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*
D004317:Doxorubicin